AWH vs. LEXX, AKTX, LSTA, CVKD, VRCA, CMMB, JATT, OMGA, MRNS, and CVM
Should you be buying Aspira Women's Health stock or one of its competitors? The main competitors of Aspira Women's Health include Lexaria Bioscience (LEXX), Akari Therapeutics (AKTX), Lisata Therapeutics (LSTA), Cadrenal Therapeutics (CVKD), Verrica Pharmaceuticals (VRCA), Chemomab Therapeutics (CMMB), JATT Acquisition (JATT), Omega Therapeutics (OMGA), Marinus Pharmaceuticals (MRNS), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry.
Aspira Women's Health vs.
Lexaria Bioscience (NASDAQ:LEXX) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
Lexaria Bioscience has higher earnings, but lower revenue than Aspira Women's Health. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 26.4% of Lexaria Bioscience shares are held by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Lexaria Bioscience had 6 more articles in the media than Aspira Women's Health. MarketBeat recorded 9 mentions for Lexaria Bioscience and 3 mentions for Aspira Women's Health. Aspira Women's Health's average media sentiment score of 0.77 beat Lexaria Bioscience's score of 0.33 indicating that Aspira Women's Health is being referred to more favorably in the news media.
Aspira Women's Health received 7 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 17.72% of users gave Aspira Women's Health an outperform vote.
Lexaria Bioscience currently has a consensus target price of $9.50, indicating a potential upside of 421.98%. Aspira Women's Health has a consensus target price of $4.40, indicating a potential upside of 994.53%. Given Aspira Women's Health's higher possible upside, analysts clearly believe Aspira Women's Health is more favorable than Lexaria Bioscience.
Aspira Women's Health has a net margin of -165.07% compared to Lexaria Bioscience's net margin of -1,473.04%. Aspira Women's Health's return on equity of 0.00% beat Lexaria Bioscience's return on equity.
Lexaria Bioscience has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
Summary
Lexaria Bioscience beats Aspira Women's Health on 10 of the 18 factors compared between the two stocks.
Get Aspira Women's Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AWH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aspira Women's Health Competitors List
Related Companies and Tools
This page (NASDAQ:AWH) was last updated on 1/31/2025 by MarketBeat.com Staff
Free AWH Stock Alerts